Introduction: Gastric Cancer (GC) is a global public health issue, characterized by its development in the cells that line the interior of the stomach. It is known that this type of cancer can be classified into two subcategories: diffuse, with cells of a more aggressive phenotype, low cohesiveness and high invasive potential; and intestinal, identified by an organized glandular structure and slower tumor progression. Currently, the treatment for GC consists mainly of chemotherapy; however, existing regimens face limitations regarding their selectivity and efficacy, which highlights the urgency for new therapeutic approaches. From this perspective, natural products have gained notoriety, among them, geopropolis, a compound produced by stingless bees and formed from a mixture of propolis with clay or soil. The heterogeneity between tumor subcategories reinforces the relevance of evaluating new pharmaceutical candidates in different cell models, considering that their molecular singularities influence treatment response. Objectives: This study sought to evaluate the cytotoxic potential of a geopropolis extract in three distinct gastric cancer cell models. Methods: For that purpose, AGP01 cells (Metastatic Gastric Adenocarcinoma), ACP02 cells (Diffuse Gastric Adenocarcinoma), ACP03 cells (Intestinal Gastric Adenocarcinoma) and HEK-293 cells (Non-neoplastic Human Embryonic Kidney) were subjected to the MTT cell viability assay following a 72-hour treatment with concentrations of: 100 ?g/mL, 50 ?g/mL, 25 ?g/mL, 12.5 ?g/mL, 6.25 ?g/mL, 3.125 ?g/mL and 1.5625 ?g/mL of the geopropolis ethanolic extract from the Melipona seminigra pernigra (UBR) species. For data analysis, a dose-response sigmoid equation was applied using nonlinear regression to determine the mean inhibitory concentration (IC50), with GraphPad Prism v9 software. Additionally, group comparisons were performed using one-way ANOVA, followed by Bonferroni correction, with the significance level set at 95% (p<0.05). Results: Our results demonstrated that the geopropolis extract from the UBR species exhibited differential cytotoxic activity across the evaluated cell lines, with an IC50 of 8.3 ?g/mL for AGP01, 37.8 ?g/mL for ACP02, 20.8 ?g/mL for ACP03, and 22.2 ?g/mL for HEK-293, displaying a selective treatment profile only for AGP01. Conclusion: In regard to the observed results, we suggest that the geopropolis extract from the UBR species presents significant cytotoxic activity in gastric cancer cell lines, but with selectivity only toward the metastatic cell. Still, the cytotoxic activity observed in ACP02 and ACP03 cells indicates that the extract also exerts relevant biological effects in different cellular contexts. This response may be associated with the chemical composition of the sample, notoriously rich in phenolic compounds and flavonoids, known for their antiproliferative, antioxidant and pro-apoptotic properties, Thus, the extract emerges as a promising candidate for the development of new antineoplastic therapies, although further research is necessary to characterize its mechanisms of action and establish its safety and efficacy in preclinical trials.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
